Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Profit After Tax (2016 - 2025)

Arrowhead Pharmaceuticals' Profit After Tax history spans 16 years, with the latest figure at $28.2 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 116.32% year-over-year to $28.2 million; the TTM value through Dec 2025 reached $225.4 million, up 134.6%, while the annual FY2025 figure was $30.1 million, 104.94% up from the prior year.
  • Profit After Tax reached $28.2 million in Q4 2025 per ARWR's latest filing, up from $8.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $367.9 million in Q1 2025 to a low of -$180.7 million in Q3 2024.
  • Average Profit After Tax over 5 years is -$53.2 million, with a median of -$67.7 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: tumbled 366.37% in 2024, then surged 389.67% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$62.9 million in 2021, then soared by 33.5% to -$41.8 million in 2022, then crashed by 223.78% to -$135.4 million in 2023, then dropped by 27.86% to -$173.1 million in 2024, then soared by 116.32% to $28.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Profit After Tax are $28.2 million (Q4 2025), $8.0 million (Q3 2025), and -$178.7 million (Q2 2025).